Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...

Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV ... s first-in-class anti-RSV mAb ...

It comes as the UK Health Security Agency (UKHSA) published its first annual report detailing the infectious diseases ...

Blue Lake Biotechnology About RSV Respiratory syncytial virus (RSV) is a highly contagious and common respiratory virus and one of the leading causes of acute respiratory disease, infecting more ...

Dame Jenny warned many other diseases are “out of step from the pandemic or moving in the wrong direction". The report also ...

The report also comes as the NHS emerges from challenging winter months, which saw a so-called “quad-demic” of flu, Covid-19, respiratory syncytial virus ... as our world-class vaccination ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine ... “While mResvia may not have a best-in-class efficacy profile, we still see a significant market opportunity ...

Publication of the report comes as the health service emerges from the winter months, which saw a so-called “quad-demic” of disease; flu, Covid-19, respiratory syncytial virus (RSV ...

respiratory syncytial virus (RSV) and pertussis, or whooping cough. “I won’t say that it’s kind of a perfect storm, but I just know there is a lot of respiratory disease happening in South ...